To Top

Search By Topic

Contract Research (CRO)

153 Articles available
Expansion

Optimapharm, Europe’s fast-growing CRO, expands office network to US and Hungary

PR-M06-18-NI-035
Novel Medicine

WuXi Laboratory Testing Division: Propelling Innovation and Better Treatments for Patients

PAO-M05-18-CL-004
Strategic Partnership

Charles River Laboratories to Expand Partnership with PathoQuest

PAO-M04-18-NI-011
Acquisition

Citoxlab Acquires Solvo Biotechnology    

PAO-M03-18-NI-025
CRO

Diurnal Selects Worldwide Clinical Trials as Preferred CRO Provider

PR-M03-18-NI-050
Discovery

A New Landscape: M&A in the Discovery & Research Sector

PAP-Q1-18-NI-002
Oncology

Charles River Laboratories Announces New Online Tool

PAO-M03-18-NI-003
Appointment

Charles River Laboratories Announces Executive Management Appointments

PR-M02-18-NI-58
Acquistion

Charles River Laboratories to Acquire MPI Research

PR-M02-18-NI-57
Investment

Contract Research Organization Growth and Investment

APR-M10-17-NI-001
Acquistion

Charles River Laboratories Acquires KWS BioTest

PR-M01-18-NI-040
Immunology

Charles River Laboratories Gains Immunology Contract Research Services

PAO-M01-18-NI-023
Clinical Trials

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

PR-M01-18-NI-035
Bioequivalence Study

Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis® Orally Dissolving Tablet

PR-M01-18-NI-034
Joint Venture

WuXi AppTec Group and Mayo Clinic Form Joint Venture to Deliver Clinical Diagnostic Services

PR-M01-18-NI-027
Hires

AMRI Names Michael Mulhern as Chief Executive Officer

PR-M01-18-NI-012
Business

PPD Names Colin Hill, CEO of GNS Healthcare, to its Board of Directors

PR-M01-18-NI-007
FDA Guidance

FDA Received Numerous Comments on Its Draft Guidance for Evaluating Biosimilarity

PAO-M01-18-NI-004
Research

Tumor Killing Combo Wins Third U.S. Patent

PAO-M12-17-NI-033
Mergers & Acquistions

Five Critical Considerations for Pharmaceutical M&A

PAO-M12-17-Cl-001
Drug Development

Thermo Fisher Scientific’s Patheon Division to Manufacture Nasal Formulation for Evoke Pharma

PAO-M12-17-NI-003
Strategic Partnership

New Collaboration Targets the Development of Oligonucleotides

PAO-M12-17-NI-002
Clinical Research

CRO Pharmaceutical Product Development Wins NIH Contract for HIV Research

PAO-M11-17-NI-021
CRO

CitoxLab acquires Xenometrics, an American CRO specialized in preclinical assessment of new drug candidates

PR-M10-17-NI-010
CRO

Factory CRO Acquires MileStone Research Organization, Builds North American Presence

PR-M10-17-NI-010
Drug Discovery

Forge Therapeutics and Evotec Expand Their Partnership

PAO-M10-17-NI-041
FDA

FDA Holds First Patient Engagement Advisory Committee Meeting

PAO-M10-17-NI-023
CRO

Society for Clinical Research Sites Announces Winning Sponsor and CRO of 2017 Eagle Award — Eli Lilly and INC Research/InVentiv Health

PR-M10-17-NI-006
CDMO CRO

New CDMO/CRO Collaboration Announced

PAO-M09-17-NI-026
Insightful Integration

Combining Content and Research in a Single Website Platform

PAP-Q3-17-NI-001
CRO

Building Strategic Sponsor-CRO Partnerships: The International Element Changing Clinical Trials

PAP-Q3-17-FA-002
Acquistion

Brains On-Line Acquired by Charles River Laboratories for $21 million

PAO-M08-17-NI-017
Strategy

Icagen on the Road to BIO: Early-Stage Planning for End-Stage Success

Kenneth F. Wertman Ph.D., Senior Vice President, Icagen. View more about Icagen on the Road to BIO.

PTV-M06-17-CL-012
CRO

CRO’s Move to Fill the Gap

PAO-M06-17-NI-006
Clinical Trial

Expanding Into Clinical Trials

Jeff Schwegman, CEO, AB Biotechnologies 

PTV-M03-17-IN-012
CDMO

Upcoming: Women in Leadership Forum

PAO-M04-17-NI-023
Clinical Trials

Advancing Clinical Trial Efficiency with Electronic Informed Consent

APR-M03-17-NI-001
CRO

What’s New in Bioanalysis?

Chad Briscoe, Executive Director, PRA Health Sciences

PTV-M11-16-AP-019
Formulation

Partnering for Formulation Development

Elsie Melsopp, Director of Formulation, Alcami

PTV-M11-16-AP-001
Innovation

The Latest Developments at Triskelion

Tineka Meijers, VP, Business Development, Triskelion, TNO Predictive Health Technologies

PTV-M11-16-AP-004
Discovery

Disease in a Dish: Creating Human Tissues In Vitro

Paul August, Ph.D, Vice President Biology, Icagen

PTV-M11-16-AP-014
CRO

Charles River Announces NCG Mouse Model

PAO-M04-17-NI-007
CRO

Solvias Continues on Growth Path

PAO-M03-17-NI-003
CRO

PPD Offers Apprenticeships to Military Veterans

PAO-M03-17-NI-001
Outsourcing

Analytical Testing Outsourcing Trends Update

CPP-M03-17-NI-001
CDMO

The Data Generation

PAP-Q1-17-IN-001
CDMO

Industry Benchmark: Introduction

PAP-Q1-17-FA-001
Outsourcing

Spending on Contract Research Services Slowing Down

PAP-Q1-17-FA-003
CDMO

Investors May Look Smaller

PAP-Q1-17-FA-008
CDMO

2017 Top 5 Industry Leader

PAP-Q1-17-IL-001
CDMO

Q: What Challenges are Associated with Implementing Cloud Computing within CROs/CDMOs?

PAP-Q1-17-RT-004
Outsourcing

Integrated Innovation: Fostering the New Growth in Pharma

PAP-Q1-17-CL-003
API

Spray Drying Enhances Solubility and Bioavailability

PMO-M01-17-NI-001
Equipment

Environmental Monitoring: An Evolving Process for Today’s Evolving Production

POP-M11-16-NI-001
Outsourcing

2016 CRO Industry Leaders

PAP-Q1-16-IL-002
Outsourcing

Expanding Trial Data Demands New Analytical Methods

MCP-M09-16-NI-001
Biologics

INNOVATION: Creating Solutions for Healthcare’s Ambitious Agenda

PAP-Q04-16-FA-001
CDMO

A Foundation of Innovation

PAP-Q04-16-IN-001
CDMO

Nice Insight Launches 2017 Study Season

PAP-Q04-16-NI-001
CDMO

Seeking Quality Deals: Consolidation and Acquisition

PAP-Q04-16-VP-002
CDMO

Nice Insight Overview: The Key to Pharma’s Next Generation Success

PAP-Q03-16-NO-001
CDMO

Collaboration is the Name of the Game

PAP-Q03-16-IN-001
CDMO

Effective Quality Assurance Capabilities Essential for CDMO/CRO Success

MCP-M07-16-NI-001
Supply Chain

Strong Growth for CRO Market; Tox Testing Poses Challenges

SCP-M07-16-NI-001
CDMO

Improving Packaging Processes to Meet Regulatory and Patient Needs

CPP-M06-16-NI-001
CDMO

Sponsor Company Size Influences Contract Service Provision

POP-M05-16-NI-001
CDMO

Increasing the Chances of Finding the Best Possible CRO/CMO Fit

MCP-M05-16-NI-001
Outsourcing

Ways to Lower Costs of Clinical Trials and How CROs Help

APR-M04-16-NI-001
CDMO

Research Database Recommendations

PAP-Q02-16-NI-001
API

Look for More Outsourcing of Research Activities in 2016

APR-M01-16-NI-002
Quality

Opportunities Abound for Contract Services in 2016

PAP-Q1-16-NO-001
Outsourcing

Another Exciting Year for Clinical Research Outsourcing

PAP-Q1-16-FA-002
CMO

Special Focus-Achieving Strong Customer Perception: The Customer Experience

PAP-Q4-15-VP-001
API

Bolstering Capabilities for Parenteral Drug Development and Manufacturing

PAP-Q4-15-CL-005
Biologics

Be Innovative! Maneuvering the Global Pharmaceutical Market

PAP-Q4-15-NO-001
CDMO

A Look At 2015 Outsourcing Trends And What To Expect In 2016

LSL-M10-15-NI-001
Biopharmaceuticals

Manufacturers and CMOs Streamline Bioprocessing with Single-Use Devices

POP-M09-15-NI-001
Outsourcing

Advanced Technologies Cited as Essential for Clinical Trial Challenges

LSL-M09-15-NI-001
API

Suiting a Strategy to Fit Biotech Behaviours

MCP-M07-15-NI-001
Outsourcing

Nice Insight Survey: Focus on Automated Laboratory Systems

POP-M07-15-NI-001
CDMO

Environmental Monitoring Benefits from Technological Innovation

APR-M07-15-NI-001
Outsourcing

Outsourcing Increasing To CROs And CMOs Known For Quality And Cost-Effectiveness

LSL-M07-15-NI-001
API

Biologics Account for an Increasing Share of Outsourcing Spending

MCP-M06-15-NI-001
Biologics

CRO Outsourcing Trends For 2015: The Move to the Cloud, the Web and Mobile Technology Continues

POP-M05-15-NI-001
Outsourcing

CRO or CMO: Which Is Best For Your Preformulation Needs?

LSL-M05-15-NI-001
Outsourcing

Leads Ways of selecting CMOs and CROs

MCP-M04-15-NI-001
Clinical Trials

Cost Forecasting for Clinical Trial Management

PAP-APR-S01-CL-004
Equipment

Trusted Partnerships Key to Leveraging Full Benefits of Surplus Pharmaceutical Equipment Market

PAP-APR-S01-CL-005
Outsourcing

Biopharmaceutical Outsourcing To CROs In Emerging Markets Surges For 2015

LSL-M03-15-NI-002
CDMO

What Does 2015 Hold For The Indian CMO Industry?

LSL-M03-15-NI-003
Equipment

Ensuring Profitability Through Strategic Decision Making

MCP-M03-15-NI-001
Outsourcing

Identifying Segmentation Within the Pharmaceutical Outsourcing Market

POP-M02-15-NI-001
CDMO

The CDMO Model And Outsourcing Development

LSL-M02-15-NI-001
CMO

Reaping the Benefits of Economies of Scale

MCP-M01-15-NI-001
Outsourcing

Innovation Moves Up in Rank and Technologies Move into the Outsourcing Paradigm

LSL-M01-15-NI-001
Outsourcing

A Recap on 2014 Outsourcing Trends and What to Expect in 2015

LSL-M12-14-NI-001
Outsourcing

Is Discounting Services Good for Drug Development?

LSL-M10-14-NI-001
Outsourcing

The Continued Evolution of the Sponsor-CRO Relationship

LSL-M08-14-NI-001
Outsourcing

Emerging Pharma and Emerging Biotech Value Different Traits in CROs

LSL-M08-14-NI-002
Outsourcing

Sponsors Not the Only Party to Benefit from Clinical Trials in Emerging Markets

POP-M06-14-NI-001
Outsourcing

Can CROs Help Reduce the Expense of Clinical Trials?

LSL-M05-14-NI-001
Biologics

Outsourcing To CROs And CMOs In Emerging Markets In 2014

CIO-M01-14-NI-002
Outsourcing

What Can 2013 Outsourcing Trends Lead Us to Expect In 2014

LSL-M12-13-NI-001
Biologics

Using 2013 Trends by Buyer Group to Plan Your Outsourcing Initiatives

CIO-M11-13-NI-001
Biologics

Outsourcing Biomanufacturing

CIO-M09-13-NI-001
Outsourcing

The Top CROs by Therapeutic Indication Share Strong Regulatory and Productivity Performance

LSL-M09-13-NI-001
Biologics

CROs and CMOs Continuing Drug Delivery Innovation

CIO-M08-13-NI-001
Outsourcing

Trends In Outsourcing — What’s Going On In Big Pharma

LSL-M06-13-NI-001
Outsourcing

Quality and Reliability Will Continue to Drive Outsourcing Relationships in 2013

CIO-M04-13-NI-001
Outsourcing

Outsourcing Clinical Research — Trends by Customer Group

LSL-M03-13-NI-001
Outsourcing

The Evolving Dynamic Of The Sponsor-CRO Relationship

CIO-M12-12-NI-001
Outsourcing

How Relevant are 483s in Terms of Compliance Perception?

CIO-M11-12-NI-001
Outsourcing

Strategic Partnering for Innovation

CIO-M10-12-NI-001
Outsourcing

A Diversified Portfolio of Contract Providers Might Improve Results

LSL-M03-13-NI-002
Outsourcing

The Right Preformulation / Formulation Outsourcing Partner Can Alleviate Challenges To Reducing Costs

CIO-M09-12-NI-001
Outsourcing

CROs & CMOs: Focusing On Innovation

LSL-M05-12-NI-001
Clinical Trials

Data Management and Information Technology — Do the Benefits Outweigh the Risks?

LSL-M05-12-NI-001
Outsourcing

Advancing Sponsor/CRO Collaborations to Improve Preclinical Throughput

LSL-M05-12-NI-002
Outsourcing

Outsourcing Clinical Research: Established vs. Emerging Markets

PPO-M05-12-NI-001
Outsourcing

Key Drivers for Outsourcing Partner Selection

LSL-M02-12-NI-001
Outsourcing

Best Practices for Targeted Marketing Communications

DDD-M01-12-NI-001
Biologics

Spending Trends in the CMO and CRO Market

PPO-M01-12-NI-001
Outsourcing

Optimizing the Partner Selection Process for Drug Developers

LSL-M12-11-NI-002
Outsourcing

Who Should Be Doing Your Pharmaceutical Analytical Testing — a CRO or CMO?

PPO-M12-11-NI-001
Clinical Trials

Overcoming Barriers to Forming Successful Relationships with CMOs in Emerging Markets

PQO-M12-11-NI-001
Outsourcing

What CROs and CMOs Can Learn from Q3 Outsourcing Data and 2011 Trends

PQO-M11-11-NI-001